Literature DB >> 8993079

Overview of somatization: diagnosis, epidemiology, and management.

J I Escobar1.   

Abstract

This article outlines critical issues in the psychiatric assessment of patients presenting with medically unexplained physical symptoms that form the core of the somatoform disorders in current nosologies. The prevalence of these disorders in communities and clinical settings emphasizes that a majority of these patients are primary care service users rather than mental health clients. A brief review of previous studies on the pharmacological management of these syndromes with antidepressants highlights unique features of these disorders that are relevant to the design of double-blind studies. The promising results emerging from some of these studies bring new excitement to the field that may help counter the prevailing therapeutic nihilism, thus attracting new investigators to this area. Finally, several caveats are provided on issues of research design and interpretation for the benefit of those entering this field of research.

Entities:  

Mesh:

Year:  1996        PMID: 8993079

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  4 in total

1.  Somatization Disorder.

Authors:  Donald M. Hilty; James A. Bourgeois; Celia H. Chang; Mark E. Servis
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

2.  Factor analysis of the clustering of common somatic symptoms: a preliminary study.

Authors:  Chung-Huang Tsai
Journal:  BMC Health Serv Res       Date:  2010-06-10       Impact factor: 2.655

3.  A randomized clinical trial of a care recommendation letter intervention for somatization in primary care.

Authors:  W Perry Dickinson; L Miriam Dickinson; Frank V deGruy; Deborah S Main; Lucy M Candib; Kathryn Rost
Journal:  Ann Fam Med       Date:  2003 Nov-Dec       Impact factor: 5.166

4.  A 37-year-old mechanic with multiple chemical sensitivities.

Authors:  H M Kipen; N Fiedler
Journal:  Environ Health Perspect       Date:  2000-04       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.